Biotech Values

[mcbio]

SQNM

The company said that it is expecting revenues of $89M, equating to a Y/Y growth rate of 59%, but the results were largely overshadowed by Illumina's (ILMN -7.3%) acquisition of Verinata, whose competing verifi test - which analyzes fetal DNA naturally found in a pregnant women's blood to look for missing or extra copies of chromosomes - carry's less risk than Sequenom’s SEQureDx technology

Doesn't SQNM's MaterniT21 test do this very same thing? See: http://www.sequenomcmm.com/Home/health-care-providers/Trisomy-21/About-the-Test .